

NCT02979561 comparison:

Summary:
CHIA has 27 criteria while your personal folder has 27 criteria
Total found criteria: 27/27
Total not Found: 0/27
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Men and women aged > 18 years                      │ Men and women aged \> 18 years                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Angiographically confirmed acute massive pulmonary │ Angiographically confirmed acute massive pulmonary │
│ embolism with involvement of Central pulmonary     │ embolism with involvement of Central pulmonary     │
│ arteries                                           │ arteries                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ endovascular mechanical thrombus fragmentation +   │ endovascular mechanical thrombus fragmentation +   │
│ thrombolytic therapy (using recombinant tissue     │ thrombolytic therapy (using recombinant tissue     │
│ activator of plasminogen), performed for treatment │ activator of plasminogen), performed for treatment │
│ of the above-mentioned pulmonary embolism in less  │ of the above-mentioned pulmonary embolism in less  │
│ than 48 hours before randomization. The patient    │ than 48 hours before randomization. The patient    │
│ should be randomized no earlier than 24 hours      │ should be randomized no earlier than 24 hours      │
│ after procedures endovascular mechanical thrombus  │ after procedures endovascular mechanical thrombus  │
│ fragmentation + thrombolytic therapy               │ fragmentation + thrombolytic therapy               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Written informed consent signed by patient         │ Written informed consent signed by patient         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signs of hemodynamic instability (i.e. systolic    │ Signs of hemodynamic instability (i.e. systolic    │
│ blood pressure <100 mm Hg.St. or episode of        │ blood pressure \<100 mm Hg.St. or episode of       │
│ systolic blood pressure fall for =40 mm Hg. / or   │ systolic blood pressure fall for ≥40 mm Hg. / or   │
│ heart rate > 110 lasting more than 15 min) or need │ heart rate \> 110 lasting more than 15 min) or     │
│ for ventilatory support within 12 hours prior to   │ need for ventilatory support within 12 hours prior │
│ randomisation                                      │ to randomisation                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The indication for oral anticoagulation,           │ The indication for oral anticoagulation,           │
│ associated with others disease                     │ associated with others disease                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ malignant neoplasm of any location                 │ malignant neoplasm of any location                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraindications to warfarin or pradaxa according │ Contraindications to warfarin or pradaxa according │
│ to Russian Instructions for medical use of these   │ to Russian Instructions for medical use of these   │
│ drugs                                              │ drugs                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Indications for concomitant treatment with         │ Indications for concomitant treatment with         │
│ antiplatelet agents                                │ antiplatelet agents                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any stroke within 6 months before randomization    │ Any stroke within 6 months before randomization    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Intracranial hemorrhage in anamnesis               │ Intracranial hemorrhage in anamnesis               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active bleeding, bleeding diathesis                │ Active bleeding, bleeding diathesis                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant bleeding within the last 30 │ Clinically significant bleeding within the last 30 │
│ days                                               │ days                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Trauma or extensive surgery within 1 month before  │ Trauma or extensive surgery within 1 month before  │
│ randomization or surgery planned in the next 6     │ randomization or surgery planned in the next 6     │
│ months after randomization                         │ months after randomization                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Intracranial pathology: tumor, arteriovenous       │ Intracranial pathology: tumor, arteriovenous       │
│ fistula or aneurysm                                │ fistula or aneurysm                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Gastrointestinal bleeding in the previous 3 months │ Gastrointestinal bleeding in the previous 3 months │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Gastric ulcer or duodenal ulcer with clinical      │ Gastric ulcer or duodenal ulcer with clinical      │
│ manifestations or endoscopically identified acute  │ manifestations or endoscopically identified acute  │
│ ulcer without signs of scarring during previous 30 │ ulcer without signs of scarring during previous 30 │
│ days                                               │ days                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled hypertension (systolic blood          │ Uncontrolled hypertension (systolic blood          │
│ pressure> 180 mm Hg. and / or diastolic blood      │ pressure\> 180 mm Hg. and / or diastolic blood     │
│ pressure> 100 mm.hg in patients receiving          │ pressure\> 100 mm.hg in patients receiving         │
│ antihypertensive drugs)                            │ antihypertensive drugs)                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy, lactation                               │ Pregnancy, lactation                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy <6 months                          │ Life expectancy \<6 months                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant liver disease               │ Clinically significant liver disease               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Creatinine clearance (estimated by Cockcroft-      │ Creatinine clearance (estimated by Cockcroft-      │
│ Gault) <30 ml / min                                │ Gault) \<30 ml / min                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ hemoglobin level <90 g/l), thrombocytopenia        │ hemoglobin level \<90 g/l), thrombocytopenia       │
│ <100x10^9 / L                                      │ \<100x10\^9 / L                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who, in the opinion of the researcher,    │ Patients who, in the opinion of the researcher,    │
│ are not suitable for inclusion in the study, for   │ are not suitable for inclusion in the study, for   │
│ example, due to the low likelihood of doctor's     │ example, due to the low likelihood of doctor's     │
│ recommendations following                          │ recommendations following                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Long-term use of NSAIDs                            │ Long-term use of NSAIDs                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current participation in another clinical study    │ Current participation in another clinical study    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Allergic to contrast substance or radioisotope     │ Allergic to contrast substance or radioisotope     │
│ drugs used in procedures to assess endpoints of    │ drugs used in procedures to assess endpoints of    │
│ the study, which according to researchers, may be  │ the study, which according to researchers, may be  │
│ a contraindication to the implementation of these  │ a contraindication to the implementation of these  │
│ research methods                                   │ research methods                                   │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
├───────────────────────────────────┤
│ Must have maximum age of 80 Years │
╘═══════════════════════════════════╛